Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Licensing fee revenue	$ 200,000
Costs and expenses:
General and administrative costs, including $99,901 and $784,598 to related parties for the years ended December 31, 2015 and 2014, respectively	754,440	$ 1,285,173
Research and development costs, including $970,729 and $435,707 to Theradex for the years ended December 31, 2015 and 2014, respectively	2,091,973	1,117,970
Total costs and expenses	2,846,413	2,403,143
Loss from operations	(2,646,413)	(2,403,143)
Interest income	78	66
Fair value of warrant extensions	(34,016)	(302,691)
Fair value of warrant discount	$ (171,757)	(134,420)
Gain from reversal of registration rights penalty obligation		74,000
Net loss	$ (2,852,108)	$ (2,766,188)
Dividend on Series A Convertible Preferred Stock	(2,000)
Net loss attributable to common stockholders	$ (2,854,108)	$ (2,766,188)
Net loss per common share - basic and diluted	$ (0.06)	$ (0.06)
Weighted average common shares outstanding - basic and diluted	46,793,502	44,405,563